title: Anti-inflammatory activity of (E)-1-(3,4-dimethoxyphenyl) butadiene from Zingiber cassumunar Roxb.
abstract: This study aimed to investigate the anti-inflammatory activity of (E)-1-(3,4-dimethoxyphenyl) butadiene (DMPBD), isolated from Zingiber cassumunar Roxb., using in vivo and in vitro models. The results show that DMPBD dose-dependently inhibited the rat ear edema induced by ethyl phenylpropiolate (EPP), arachidonic acid (AA) and 12-O-tetradecanoylphorbol 13-acetate (TPA) and it was more potent than any other standard drugs being used. In EPP-induced edema IC(50) of DMPBD and oxyphenbutazone were 21 and 136nmol per ear, respectively. The IC(50) of DMPBD and phenidone were 60 and 2520nmol per ear, respectively, in AA-induced edema whereas DMPBD was 11 times more potent than diclofenac in TPA-induced edema (IC(50)=660 and 7200pmol per ear, respectively). DMPBD and diclofenac inhibited the rat paw edema induced by carrageenan but not by platelet activating factor (PAF). In in vitro study DMPBD, aspirin and phenidone inhibited collagen-induced platelet aggregation with IC(50) of 0.35, 0.43 and 0.03mM, respectively. Whereas IC(50) of these agents in ADP, AA and PAF inductions were 4.85, 3.98 and 1.30mM; 0.94, 0.13 and 0.04mM; and 1.14, 6.96 and 2.40mM, respectively. These results indicate that DMPBD possesses a potent anti-inflammatory activity through the inhibition of CO and LO pathways and seems to have more prominent effects on the LO pathway.
authors.affiliation: Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Muang, 65000, Phitsanulok, Thailand. rattimaj@yahoo.com
authors.forename: Rattima
authors.initials: R
authors.lastname: Jeenapongsa
authors.forename: Krongtong
authors.initials: K
authors.lastname: Yoovathaworn
authors.forename: Kittima M
authors.initials: KM
authors.lastname: Sriwatanakul
authors.forename: Ubonwan
authors.initials: U
authors.lastname: Pongprayoon
authors.forename: Kampon
authors.initials: K
authors.lastname: Sriwatanakul
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D002070:Butadienes / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D002351:Carrageenan; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy*; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D008517:Phytotherapy; D028321:Plant Preparations / Q000737:chemistry; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D030521:Zingiberaceae / Q000737:chemistry*
chemical_list: C479884:(E)-1-(3,4-dimethoxyphenyl) butadiene; D000893:Anti-Inflammatory Agents; D002070:Butadienes; D028321:Plant Preparations; D010975:Platelet Aggregation Inhibitors; D002351:Carrageenan